Related references
Note: Only part of the references are listed.Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Christopher J. Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2017)
Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia
Lian Xu et al.
BLOOD (2017)
Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia
Lian Xu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies
Michael. J. Kluk et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia
Florence Nguyen-Khac et al.
HAEMATOLOGICA (2013)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Share Paper
